Cargando…

Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma

BAY 1143572 is a highly selective inhibitor of cyclin-dependent kinase 9/positive transcription elongation factor b. It has entered phase I clinical studies. Here, we have assessed the utility of BAY 1143572 for treating natural killer (NK) cell leukemias/lymphomas that have a poor prognosis, namely...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kinoshita, Shiori, Ishida, Takashi, Ito, Asahi, Narita, Tomoko, Masaki, Ayako, Suzuki, Susumu, Yoshida, Takashi, Ri, Masaki, Kusumoto, Shigeru, Komatsu, Hirokazu, Shimizu, Norio, Inagaki, Hiroshi, Kuroda, Taruho, Scholz, Arne, Ueda, Ryuzo, Sanda, Takaomi, Iida, Shinsuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269314/ https://www.ncbi.nlm.nih.gov/pubmed/30076184 http://dx.doi.org/10.3324/haematol.2018.191395

Ejemplares similares

Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals
por: Masaki, Ayako, et al.
Publicado: (2018)

Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

Clinical significance of tryptophan catabolism in Hodgkin lymphoma
por: Masaki, Ayako, et al.
Publicado: (2017)

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma
por: Yoshida, Takashi, et al.
Publicado: (2018)

Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits
por: Yoshida, Takashi, et al.
Publicado: (2018)

Volunteer unrelated donor cell‐derived acute myeloid leukemia with RUNX1‐RUNX1T1
por: Hagiwara, Shinya, et al.
Publicado: (2021)

Exophiala dermatitidis Fungemia Diagnosed Using Time-of-flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole
por: Yoshida, Takashi, et al.
Publicado: (2019)

Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy
por: Kikuchi, Takaki, et al.
Publicado: (2020)

Acute Promyelocytic Leukemia in a Patient With Chronic Continuous Type of Crohn’s Disease
por: Kinoshita, Shiori, et al.
Publicado: (2022)

P820: POTENTIAL IMMUNOSUPPRESSIVE EFFECT OF EXTRACELLULAR VESICLES FROM PATIENTS WITH MULTIPLE MYELOMA
por: Hagiwara, Shinya, et al.
Publicado: (2023)

Expression, mutation, and methylation of cereblon‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma
por: Tachita, Takuto, et al.
Publicado: (2020)

A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

Immunohistochemistry for CCR4 C‐terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T‐cell leukemia/lymphoma
por: Fujii, Keiichiro, et al.
Publicado: (2020)

Clinical significance of CD28 gene‐related activating alterations in adult T‐cell leukaemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2020)

Clinicopathological significance of CD28 overexpression in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma
por: Murase, Takayuki, et al.
Publicado: (2019)

Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system
por: Murase, Takayuki, et al.
Publicado: (2019)

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
por: Nakayama, Takafumi, et al.
Publicado: (2020)

The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib
por: Mori, Yoshinori, et al.
Publicado: (2018)

Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment
por: Sakamoto, Yuma, et al.
Publicado: (2022)

Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy
por: Narita, T, et al.
Publicado: (2015)

Lack of Ku80 Alteration in Multiple Myeloma
por: Kato, Miyuki, et al.
Publicado: (2002)

The Positive Nuclear Staining Observed with Monoclonal Antibody against PRAD1/Cyclin D1 Correlates with mRNA Expression in Mantle Cell Lymphoma
por: Kuroda, Hiroyuki, et al.
Publicado: (1995)

Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model
por: Mori, F, et al.
Publicado: (2012)

Clinical landscape of TP73 structural variants in ATL patients
por: Hiramatsu, Hiroaki, et al.
Publicado: (2023)

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma
por: Ri, Masaki, et al.
Publicado: (2017)

Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF
por: Yano, Hiroki, et al.
Publicado: (2008)

Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma
por: Maekawa, Keiko, et al.
Publicado: (2019)

MUM1/IRF4 Expression Is an Unfavorable Prognostic Factor in B‐Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
por: Ito, Masato, et al.
Publicado: (2002)

The Relationship between Changes in Serum Element Concentrations and Pathological Condition and Disease Status in Japanese Multiple Myeloma Patients: A Pilot Study and Literature Review
por: Yamamoto, Yuko, et al.
Publicado: (2023)

Medical Decision-Making Incapacity among Newly Diagnosed Older Patients with Hematological Malignancy Receiving First Line Chemotherapy: A Cross-Sectional Study of Patients and Physicians
por: Sugano, Koji, et al.
Publicado: (2015)

Rate of Hanger Reflex Occurrence: Unexpected Head Rotation on Fronto-temporal Head Compression
por: ASAHI, Takashi, et al.
Publicado: ( 201)

Molecular Cloning of 19p13 Breakpoint Region in Infantile Leukemia with t(11;19)(q23;p13) Translocation
por: Iida, Shinsuke, et al.
Publicado: (1993)

Clonality Assay of Hematopoietic Disorders: Significance of the Buccal Epithelium as Non‐hematopoietic Control and of 95% Rejection Limit as a Novel Criterion for Monoclonality
por: Inagaki, Hiroshi, et al.
Publicado: (2001)

Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing
por: Ri, M, et al.
Publicado: (2012)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Impact of Bilateral Subthalamic Stimulation on Motor/Cognitive Functions in Parkinson's Disease
por: ASAHI, Takashi, et al.
Publicado: (2014)

The citizen preferences–positive externality trade-off: A survey study of COVID-19 vaccine deployment in Japan
por: Iida, Takashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_08ocbsojubkjvtrrr7olass3lh